丁胺卡那霉素联合头孢哌酮/舒巴坦治疗呼吸机相关肺炎的疗效

目的 探讨丁胺卡那霉素联合头孢哌酮/舒巴坦治疗VAP的有效性和安全性.方法 收集我科VAP病例62例,随机分成两组,治疗组32例和对照组30例,对照组（28例）予以头孢哌酮/舒巴坦治疗,治疗组（32例）予以丁胺卡那霉素联合头孢哌酮/舒巴坦治疗.观察和比较两组临床疗效、住院时间、不良反应和患者治疗前后血清CRP和PCT水平变化.结果 治疗组治疗总有效率为78.1%,对照组治疗总有效率为63.3%,两组比较有显著性差异（P〈0.05）;治疗组临床疗效、住院时间和患者治疗前后血清CRP和PCT水平变化等指标均明显优于对照组（P〈0.05）,有统计学意义.结论 丁胺卡那霉素联合头孢哌酮/舒巴坦治疗VAP,疗效显著、安全性高,且CRP和PCT下降显著,可作为治疗VAP的用药.

Curative effect of amikacin combined with cefoperazone/sulbactam in the treatment of patients with ventilator-associated pneumonia

Objective To evaluate the curative effect and safety of amikacin combined with cefoperazone/sulbactam in the treat- ment of patients with ventilator-associated pneumonia （VAP）. Methods 62 patients with VAP were randomly divided into the treatment group （32 cases） and the control group （30 cases）. The control group was given cefoperazone/sulbatan treatment, and the treatment group was given amikacin combined with cefoperazone/sulbactam therapy. Clinical curative effect, duration of hospital stay, adverse reac- tions and CRP and PCT changes were observed and compared between the two groups. Results The total effective rate was 78.1% in the treatment group and 63.3% in the control group respectively with significant difference （P 〈 0. 05 ）, and the improvement was more pro- nounced in the treatment group than in the control group after the treatment （ P 〈 0. 05 ）. Conclusion Amikacin combined with cefopera- zone/sulbactam is effective and safe in the treatment of patients with VAP, with the obvious decrease of PCT and CRP.